Search

Your search keyword '"Kuehm, Lindsey M."' showing total 16 results
Start Over Author "Kuehm, Lindsey M."
16 results on '"Kuehm, Lindsey M."'

2. RNA binding protein SYNCRIP maintains proteostasis and self-renewal of hematopoietic stem and progenitor cells

Author

Herrejon Chavez, Florisela, Luo, Hanzhi, Cifani, Paolo, Pine, Alli, Chu, Eren L., Joshi, Suhasini, Barin, Ersilia, Schurer, Alexandra, Chan, Mandy, Chang, Kathryn, Han, Grace Y. Q., Pierson, Aspen J., Xiao, Michael, Yang, Xuejing, Kuehm, Lindsey M., Hong, Yuning, Nguyen, Diu T. T., Chiosis, Gabriela, Kentsis, Alex, Leslie, Christina, Vu, Ly P., and Kharas, Michael G.

Published
2023
Full Text
View/download PDF

5. Data from Fructose Promotes Cytoprotection in Melanoma Tumors and Resistance to Immunotherapy

Author

Kuehm, Lindsey M., primary, Khojandi, Niloufar, primary, Piening, Alexander, primary, Klevorn, Lauryn E., primary, Geraud, Simone C., primary, McLaughlin, Nicole R., primary, Griffett, Kristine, primary, Burris, Thomas P., primary, Pyles, Kelly D., primary, Nelson, Afton M., primary, Preuss, Mary L., primary, Bockerstett, Kevin A., primary, Donlin, Maureen J., primary, McCommis, Kyle S., primary, DiPaolo, Richard J., primary, and Teague, Ryan M., primary

Published
2023
Full Text
View/download PDF

6. Data from Oxidized Lipoproteins Promote Resistance to Cancer Immunotherapy Independent of Patient Obesity

Author

Khojandi, Niloufar, primary, Kuehm, Lindsey M., primary, Piening, Alexander, primary, Donlin, Maureen J., primary, Hsueh, Eddy C., primary, Schwartz, Theresa L., primary, Farrell, Kaitlin, primary, Richart, John M., primary, Geerling, Elizabeth, primary, Pinto, Amelia K., primary, George, Sarah L., primary, Albert, Carolyn J., primary, Ford, David A., primary, Chen, Xiufen, primary, Kline, Justin, primary, and Teague, Ryan M., primary

Published
2023
Full Text
View/download PDF

7. Supplemental Figures S1-S9 from Fructose Promotes Cytoprotection in Melanoma Tumors and Resistance to Immunotherapy

Author

Kuehm, Lindsey M., primary, Khojandi, Niloufar, primary, Piening, Alexander, primary, Klevorn, Lauryn E., primary, Geraud, Simone C., primary, McLaughlin, Nicole R., primary, Griffett, Kristine, primary, Burris, Thomas P., primary, Pyles, Kelly D., primary, Nelson, Afton M., primary, Preuss, Mary L., primary, Bockerstett, Kevin A., primary, Donlin, Maureen J., primary, McCommis, Kyle S., primary, DiPaolo, Richard J., primary, and Teague, Ryan M., primary

Published
2023
Full Text
View/download PDF

8. Supplemental Figures from Oxidized Lipoproteins Promote Resistance to Cancer Immunotherapy Independent of Patient Obesity

Author

Khojandi, Niloufar, primary, Kuehm, Lindsey M., primary, Piening, Alexander, primary, Donlin, Maureen J., primary, Hsueh, Eddy C., primary, Schwartz, Theresa L., primary, Farrell, Kaitlin, primary, Richart, John M., primary, Geerling, Elizabeth, primary, Pinto, Amelia K., primary, George, Sarah L., primary, Albert, Carolyn J., primary, Ford, David A., primary, Chen, Xiufen, primary, Kline, Justin, primary, and Teague, Ryan M., primary

Published
2023
Full Text
View/download PDF

12. Fructose Promotes Cytoprotection in Melanoma Tumors and Resistance to Immunotherapy

Author

Kuehm, Lindsey M., primary, Khojandi, Niloufar, additional, Piening, Alexander, additional, Klevorn, Lauryn E., additional, Geraud, Simone C., additional, McLaughlin, Nicole R., additional, Griffett, Kristine, additional, Burris, Thomas P., additional, Pyles, Kelly D., additional, Nelson, Afton M., additional, Preuss, Mary L., additional, Bockerstett, Kevin A., additional, Donlin, Maureen J., additional, McCommis, Kyle S., additional, DiPaolo, Richard J., additional, and Teague, Ryan M., additional

Published
2021
Full Text
View/download PDF

13. Oxidized Lipoproteins Promote Resistance to Cancer Immunotherapy Independent of Patient Obesity

Author

Khojandi, Niloufar, primary, Kuehm, Lindsey M., additional, Piening, Alexander, additional, Donlin, Maureen J., additional, Hsueh, Eddy C., additional, Schwartz, Theresa L., additional, Farrell, Kaitlin, additional, Richart, John M., additional, Geerling, Elizabeth, additional, Pinto, Amelia K., additional, George, Sarah L., additional, Albert, Carolyn J., additional, Ford, David A., additional, Chen, Xiufen, additional, Kline, Justin, additional, and Teague, Ryan M., additional

Published
2021
Full Text
View/download PDF

16. High-Dimensional Analyses Reveal IL15 Enhances Activation of Sipuleucel-T Lymphocyte Subsets and Reverses Immunoresistance.

Author

Saeed MA, Peng B, Kim K, Rawat K, Kuehm LM, Siegel ZR, Borkowski A, Habib N, Van Tine B, Sheikh N, Tuyen V, Thorek DLJ, Fehniger TA, and Pachynski RK

Subjects
Animals, Male, Humans, Mice, Cell Line, Tumor, T-Lymphocyte Subsets immunology, T-Lymphocyte Subsets metabolism, Prostatic Neoplasms, Castration-Resistant immunology, Prostatic Neoplasms, Castration-Resistant therapy, Prostatic Neoplasms, Castration-Resistant pathology, Immunotherapy, Adoptive methods, Interleukin-15 pharmacology, Tissue Extracts pharmacology, Lymphocyte Activation immunology
Abstract

Sipuleucel-T (sip-T) is the only FDA-approved autologous cellular immunotherapy for metastatic castration-resistant prostate cancer (mCRPC). To elucidate parameters of the response profile to this therapy, we report high-dimensional analyses of sip-T using cytometry by time of flight (CyTOF) and show a lymphoid predominance, with CD3+ T cells constituting the highest proportion (median ∼60%) of sip-T, followed by B cells, and natural killer (NK) and NKT cells. We hypothesized that treatment of sip-T with homeostatic cytokines known to activate/expand effector lymphocytes could augment efficacy against prostate tumors. Of the cytokines tested, IL15 was the most effective at enhancing activation and proliferation of effector lymphocytes, as well as augmenting tumor cytotoxicity in vitro. Co-culture of sip-T with IL15 and control or prostate-relevant antigens showed substantial activation and expansion of CD8+ T cells and NKT cells in an antigen-specific manner. Adoptive transfer of IL15-treated sip-T into NSG mice resulted in more potent prostate tumor growth inhibition compared with control sip-T. Evaluation of tumor-infiltrating lymphocytes revealed a 2- to 14-fold higher influx of sip-T and a significant increase in IFNγ producing CD8+ T cells and NKT cells within the tumor microenvironment in the IL15 group. In conclusion, we put forward evidence that IL15 treatment can enhance the functional antitumor immunity of sip-T, providing rationale for combining IL15 or IL15 agonists with sip-T to treat patients with mCRPC., (©2024 American Association for Cancer Research.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results